Friday, 16 October 2026European Markets

COVIVIO HOTELS And TOUR EIFFEL Have A High Dividend Yield And Return On Equity In The Real Estate Sector.

Loading stream...

(vianews) - covivio hotels (covh.pa) is among this list of stock assets with the highest dividend rate and return on equity on the real estate sector.

financial asset price forward dividend yield return on equity
covivio hotels (covh.pa) €17.35 7.04% 14.02%
tour eiffel (eiff.pa) €14.90 4.93% 0.54%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. covivio hotels (covh.pa)

7.04% forward dividend yield and 14.02% return on equity

covivio hotels specializes in owning business premises in the hotel sector. a listed real estate investment company (siic), a real estate partner of the major players in the hotel industry, covivio hotels holds assets worth eur 6.6 billion (at end 2022). covivio hotels is graded bbb+ / stable outlook by standard and poor's.

earnings per share

as for profitability, covivio hotels has a trailing twelve months eps of €3.23.

pe ratio

covivio hotels has a trailing twelve months price to earnings ratio of 5.37. meaning, the purchaser of the share is investing €5.37 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 14.02%.

moving average

covivio hotels's worth is higher than its 50-day moving average of €17.26 and higher than its 200-day moving average of €16.11.

revenue growth

year-on-year quarterly revenue growth grew by 31.1%, now sitting on 324.94m for the twelve trailing months.

more news about covivio hotels.

2. tour eiffel (eiff.pa)

4.93% forward dividend yield and 0.54% return on equity

société de la tour eiffel is an integrated property company with €1.8bn in assets and a powerful service culture. an agile operator, it works across multiple asset classes (offices, logistics, managed residential, retail) located in greater paris and the major regional metropolises. it is active throughout the real estate cycle, supporting its tenants, companies of all sizes and sectors, via a rigorous direct management process. société de la tour eiffel takes a pro- active cross-disciplinary approach to csr that is fully integrated with its business strategy.

earnings per share

as for profitability, tour eiffel has a trailing twelve months eps of €0.24.

pe ratio

tour eiffel has a trailing twelve months price to earnings ratio of 62.08. meaning, the purchaser of the share is investing €62.08 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 0.54%.

dividend yield

as claimed by morningstar, inc., the next dividend payment is on jun 13, 2023, the estimated forward annual dividend rate is 0.75 and the estimated forward annual dividend yield is 4.93%.

more news about tour eiffel.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com